The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer immunotherapy.
• ICIs function by blocking inhibitory immune receptors like PD-1, PD-L1, and CTLA-4 to enhance anti-tumor T cell responses.
• Despite their success, challenges remain in identifying patients who will benefit and predicting immune-related adverse events (irAEs).

Purpose of the Study:

• To review current research on biomarkers for predicting ICI efficacy and irAEs.
• To highlight advancements in immunotherapy and the need for predictive tools.
• To discuss the potential of novel approaches in biomarker development.

Main Methods:

• Review of current research on biomarkers for immunotherapy.
• Discussion of immune checkpoint targets (PD-1, PD-L1, CTLA-4).
• Exploration of liquid biopsy combined with mass spectrometry-based proteomics.

Main Results:

• Biomarker research is crucial for optimizing ICI therapy.
• Liquid biopsy coupled with proteomics shows promise for identifying predictive biomarkers.
• These advancements aim to improve patient selection and safety in immunotherapy.

Conclusions:

• Developing effective biomarkers is essential for advancing immunotherapy.
• Liquid biopsy and proteomics offer a promising avenue for biomarker discovery.
• These efforts will lead to more personalized and safer cancer treatments.